-
The full text is here!
Time of Update: 2021-06-22
Committee on June 10. It has eight chapters and 57 articles, covering trade freedom and convenience, investment freedom and convenience, and fiscal taxation. The core points and full text of the system, ecological environment
-
Ruike Biotechnology completes nearly RMB 1 billion in Series C financing
Time of Update: 2021-06-22
> . > Ruike Biotechnology was formed by the merger of Jiangsu Ruike Biotechnology Co. , Ltd. and Beijing Anbaisheng Biotechnology Co. , Ltd. , focusing
-
Are the suddenly popular digital therapies and digital medicines really reliable...
Time of Update: 2021-06-22
/>. Luo Xiaobin said that MyoHealth’s advantage is that “our digital therapy products have been organically combined with commercial insurance, and a clearer payer has been found, which proves its actual effectiveness
-
Guocai "Renewal Season": "Shanghai Plan" is here!
Time of Update: 2021-06-22
categories> > 01 Formation of a price mechanism guided by centralized drug procurement >01 Formation of a price mechanism guided by centralized drug procurement
-
Merck Keytruda was approved for the 7th indication in China, the first-line treatment of colorectal cancer!
Time of Update: 2021-06-22
> . The approval of the new indication for pembrolizumab is based on data from the key global phase 3 clinical trial KEYNOTE-177 . </span
-
Zejing Pharmaceutical's JAK inhibitor phase 2 clinical success
Time of Update: 2021-06-22
On June 11, Zejing Pharmaceutical issued an announcement stating that its Phase 2 clinical study (ZGJAK002) for the treatment of intermediate and high-risk myelofibrosis with its new
-
FDA approves Biogen's new drug for Alzheimer's disease, provokes public outrage and 3 panelists resign
Time of Update: 2021-06-22
When the world boiled over when Biogen's new Alzheimer's drug Aduhelm was approved by the US Food and Drug Administration (FDA) for marketing, the three experts on the FDA's Expert Advisory Committee left their posts "angry" .
-
Guidelines for patient reporting outcomes in FDA cancer trials, measuring five core concepts
Time of Update: 2021-06-22
standardize the evaluation of patient reported outcomes (PRO) in cancer drug registration trials. The guidelines recommend that sponsors collect five core types of PRO data . ><span
-
Merck launches two new anti-HIV drugs, Destro and Pedro in China
Time of Update: 2021-06-22
Desi Zhuo ® and Peizhuo ® respectively in January 2021 and November 2020, the Chinese State Drug Administration approval for the treatment of adult HIV-1 virus infection .
-
A large market of more than 30 billion U.S. dollars, 8 major peptide drugs in the world
Time of Update: 2021-06-22
28 billion (+5%), accounting for 85%, mainly driven by semaglutide, and the company’s global diabetes market share has increased To 29%; other biopharmaceuticals revenue is 3.
-
The FDA is disappointed with the slow progress in the application of stem cell therapy and will strengthen law enforcement against the sale of unapproved products
Time of Update: 2021-06-22
[FDA announced a comprehensive regenerative medicine policy framework 2017/11/18] Bryan said that for the manufacturers of these products, the period of law enforcement discretion is now over .
-
Ruiming New Medicine has completed nearly 100 million yuan in A+ round of financing: promote project IND declaration and new project introduction
Time of Update: 2021-06-22
As the lead investment institution of this round, Huimei Capital will fully support the accelerated development of the company and look forward to Ruiming's new drug team to provide better treatment options for the majority of eye disease patients .
-
The national medical device adverse events surged by 130,000, but experts said it was a good phenomenon
Time of Update: 2021-06-22
Medical devices are auxiliary tools in the medical process of hospitals, which directly or indirectly act on the human body and are closely related to patient safety <br
-
Over 2 billion U.S. dollars to develop anti-TIGIT antibody GSK to add to the layout of a new generation of cancer immunotherapy
Time of Update: 2021-06-22
▲ GSK's R&D layout for the CD226 signal path (picture source: reference [2]) EOS-448 developed by iTeos is an anti-TIGIT monoclonal antibody with multiple mechanisms of action .
-
215 pharmacies in one place closed for rectification
Time of Update: 2021-06-21
supervision news, from May 19, the Municipal Market Supervision Bureau organized on-site inspections of all pharmacies in the city. During this period, 215 pharmacies that did not strictly implement the drug purchase information registration
-
Basic research on biomedicine in China is on the fast lane
Time of Update: 2021-06-21
( China News Network ) "Constructing China's Pharmaceutical Innovation Ecosystem-Part Two of the Report Series: Promoting Basic Research and Activating the Source of Innovation" (hereinafter referred to as the "Basic Research" Sub-Report") was "launched" on the 11th .
-
Application research progress of implantable drug delivery system
Time of Update: 2021-06-21
the implants in the body to form a polymer network solid or gel through heating, light, ion-mediated methods and other methods . This system has strict requirements on the reaction conditions in the body
-
Shine the audience!
Time of Update: 2021-06-18
According to reports, this is a double-blind, placebo-controlled phase 3 clinical trial aimed at evaluating the effects of adjuvant treatment with olaparib in patients with BRCA1 and BRCA2 mutations and high-risk HER2-negative primary breast cancer after adjuvant chemotherapy .
-
Throughout the 3-year history of the National Medical Insurance Administration-scientific decision-making and outstanding practice
Time of Update: 2021-06-18
Administration with its outstanding practical results . >On May 31, 2018, the National Medical Security Administration went into operation <span
-
Targeting PD-L1/TGF-β, Bioge Bio's bifunctional fusion protein obtained clinical approval from FDA
Time of Update: 2021-06-18
This is the second independent research and development product approved by the FDA after the tumor-targeting IL-15 fusion protein (BJ-001) was approved for clinical use in the United States in 2019 .
